{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:37:30Z","timestamp":1780457850187,"version":"3.54.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Over the course of a few years, a small percentage of individuals with HIV-1 develop broadly neutralizing antibodies (bnAbs) capable of neutralizing diverse viruses. Although hundreds of antibodies with neutralizing activity against heterologous viruses have been referred to as bnAbs, there is no universally accepted numerical definition of a bnAb. Here, we will review important elements of HIV neutralizing antibodies and proposed definitions of bnAbs, as well as introduce a web-based tool, CAByN (Choose Antibodies by Neutralization), allowing users to identify antibodies meeting their numerical definitions of a bnAb from data in the Los Alamos HIV Databases CATNAP (Compile, Analyze and Tally NAb Panels) antibody neutralization database. Biological findings from use of CAByN are also presented here, including differential neutralizing activity for certain antibodies across viral clades, and identification of antibodies with suspected incomplete neutralization. Website address: <jats:ext-link>http:\/\/hiv.lanl.gov\/content\/sequence\/CABYN\/CABYN.html<\/jats:ext-link>.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1624020","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:24:37Z","timestamp":1752729877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Defining criteria for broadly neutralizing HIV antibodies"],"prefix":"10.3389","volume":"16","author":[{"given":"Elizabeth-Sharon","family":"David-Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Belobrajdic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer P.","family":"Macke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey R.","family":"Quackenbush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumkum","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Mamrosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nri2674","article-title":"The immune response during acute HIV-1 infection: clues for vaccine development","volume":"10","author":"McMichael","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.01.023","article-title":"Surface-matrix screening identifies semi-specific interactions that improve potency of a near pan-reactive HIV-1-neutralizing antibody","volume":"22","author":"Kwon","year":"2018","journal-title":"Cell Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1016\/j.cell.2023.10.022","article-title":"Germinal centers output clonally diverse plasma cell populations expressing high- and low-affinity antibodies","volume":"186","author":"Sprumont","year":"2023","journal-title":"Cell."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6144","DOI":"10.1038\/ncomms7144","article-title":"Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env","volume":"6","author":"Guttman","year":"2015","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010003","article-title":"Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention","volume":"18","author":"Mayer","year":"2022","journal-title":"PloS Comput Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02732-09","article-title":"Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus","volume":"84","author":"Powell","year":"2010","journal-title":"J Virol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12091043","article-title":"HIV vaccine development at a crossroads: new B and T cell approaches","volume":"12","author":"Govindan","year":"2024","journal-title":"Vaccines (Basel)."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000442","article-title":"Neutralization tiers of HIV-1","volume":"13","author":"Montefiori","year":"2018","journal-title":"Curr Opin HIV AIDS."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708227","article-title":"To bnAb or Not to bnAb: Defining Broadly Neutralizing Antibodies Against HIV-1","volume":"12","author":"Griffith","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv404","article-title":"CATNAP: a tool to compile, analyze and tally neutralizing antibody panels","volume":"43","author":"Yoon","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.1.427-444.1996","article-title":"Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes","volume":"70","author":"Moore","year":"1996","journal-title":"J Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.04.010","article-title":"Trimeric HIV-1-env structures define glycan shields from clades A, B and G","volume":"165","author":"Stewart-Jones","year":"2016","journal-title":"Cell."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-14","article-title":"A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization","volume":"10","author":"Wang","year":"2013","journal-title":"Retrovirology."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02853-13","article-title":"Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"88","author":"deCamp","year":"2014","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.04.009","article-title":"Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers","volume":"40","author":"Falkowska","year":"2014","journal-title":"Immunity."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004271","article-title":"Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization","volume":"10","author":"Kim","year":"2014","journal-title":"PloS Pathog"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005110","article-title":"Incomplete neutralization and deviation from sigmoidal neutralization curves for HIV broadly neutralizing monoclonal antibodies","volume":"11","author":"McCoy","year":"2015","journal-title":"PloS Pathog"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02425-16","article-title":"Reduced potency and incomplete neutralization of broadly neutralizing antibodies against cell-to-cell transmission of HIV-1 with transmitted founder envs","volume":"91","author":"Li","year":"2017","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection","volume":"12","author":"Wagh","year":"2016","journal-title":"PloS Pathog"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/31514","article-title":"The antigenic structure of the HIV gp120 envelope glycoprotein","volume":"393","author":"Wyatt","year":"1998","journal-title":"Nature."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1624020\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:24:38Z","timestamp":1752729878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1624020\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1624020"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1624020","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"article-number":"1624020"}}